What’s a total !@#$ show these stocks are been at a total loss for ages
Uross03
prieš 6 mėnesius
Im in
In at 1.42
Wish me luck (if there’s any)!
Cl1f0
prieš 6 mėnesius
VOLUME IS UP⬆️⬆️⬆️
Little spike and looking at the volume there will be another soon. No merger yet but I keep saying we only need to stay above $1 for another week and then we have a high percentage of merger talks thats when we see a rocket. But thats wont be the half of it any of these private companies are looking to merge. And let me tell you they are looking for a shell. Then this is a game changer. It does have to happen to be a game changer but QNCX has the best fit out of all the shells.
1. Xaira Therapeutics
Backing: Launched in April 2024 with $1 billion in committed funding from major firms like ARCH Venture Partners and Foresite Capital.
Why it fits: It is one of the only private biotechs to actually hit the $1 billion funding mark in a single launch. They focus on AI-driven drug discovery, a high-value sector that often attracts significant investor interest.
2. Kailera Therapeutics
Backing: Has raised approximately $1 billion in total private funding as of late 2025/early 2026, including a massive $600 million Series B.
Industry Focus: Obesity (GLP-1) and related metabolic diseases.
Status: While they recently launched an IPO roadshow, many companies in this sector keep a "dual-track" strategy, meaning they evaluate reverse mergers with shells like QNCX simultaneously with IPO plans.
3. Eikon Therapeutics
Backing: Valued at approximately $3.2 billion with significant private backing from investors like T. Rowe Price and Canada Pension Plan Investment Board.
Industry Focus: Advanced microscopy and drug discovery.
Recent Activity: They recently completed an IPO in early 2026, but were long considered a primary candidate for a major public market entry.
idk30008
prieš 6 mėnesius
Can we pls see news today !!
Honestly what was the point of clearing debt and doing a 10-1 split, if this was gonna die and if we weren’t gonna stay above $1, hopefully there’s news today or tomorrow, or consider this dead
Analyst101
prieš 6 mėnesius
Somethings happening behind closed doors
cianlewis
prieš 6 mėnesius
RS completed
the halt is over, let's push
Cl1f0
prieš 6 mėnesius
RS 1-for-10 if a merger is on the cards
Ive been doing a little digging and found some previous similar scenarios all available for you to look the Internet. Because Its blown my mind how $5.5m has been paid if they expect to go bankrupt.
Therefore i think there is something in the pipeline. Everything is strictly private and no info to be given.
So asking AI to find me similar scenarios
1. MDGL 2. IRON 3. TECX 4.LH 5. BKNG
The first 3 have similar failed drug trail and then were merged after RS as a shell and not failed company, they are all above $30.72 and MDGL is $527.
I believe we have potential to be sitting pretty here. Im not selling and if it stays above $1 then we look like were have a good start. Pretty sure it has to hold for an actual handshake but this could be one of them gems. Fingers crossed. And for all you holding im with you. NFA
Šiame puslapyje gali būti bendruomenės sukurto turinio, už kurį „Trading 212“ neatsako. Visada atlik savo tyrimą. „Trading 212“ teikia tik vykdymo paslaugą, bet neteikia investavimo konsultacijų ar portfelio valdymo paslaugų.
Turto kaupimas – įprotis. Automatizuokite jį naudodami Pies.
Investuok į paruoštus arba susikurk savo investicijų rinkinius, pasirinkdamas iš daugybės vertybinių popierių ir ETF
Sužinok daugiau
Sužinok daugiau
Žiūrėti vaizdo įrašą
Turėk net brangiausių akcijų, tokių kaip „Google“, „Amazon“ ir „Apple“
Žiūrėti vaizdo įrašą
„Euronext“ Paryžius
NYSE, NASDAQ
Xetra, Gettex
Euronext Amsterdam
Bolsa de Madrid
Wiener Börse
Londono vertybinių popierių birža
„Euronext Lisbon“
„Euronext“ Paryžius
NYSE, NASDAQ
Xetra, Gettex
Euronext Amsterdam
Bolsa de Madrid
Wiener Börse
Londono vertybinių popierių birža
„Euronext Lisbon“
Peržiūrėk visas prekybos priemones
Pagalba visą parą
29 sekundžių vidutinis atsako laikas
Pradėk kaupti turtą jau dabar
Prisijunk prie daugiau nei 5 mln. naudotojų
Atsisiųsti programėlę
Atidaryti sąskaitą
Atsisiųsk mobiliąją programėlę
Visi pateikti statistiniai duomenys yra globalūs. Klientų skaičius atspindi finansuotas sąskaitas.
Puiku
Įvertinta 4,6/5, remiantis 106 426 atsiliepimais apie
Trustpilot
Įvertinta 4,6/5, remiantis 106 426 atsiliepimais apie
Trustpilot
Pakviestas
Excellent
Using Trading 212 has been a very productive and satisfying experience for me. Because the platform is user-friendly, dependable, and simple to navigate, investing is made to be a straightforward and convenient process. I am especially grateful for the user-friendly interface, the useful investment tools, and the capability to track the performance of my portfolio in real time.
Pakviestas
I have had a fantastic experience with…
have had a fantastic experience with Trading 212. The app is modern, intuitive and incredibly easy to use, making investing feel accessible and straightforward. I particularly appreciate the clear layout, real-time updates and the ability to manage my investments conveniently in one place. The overall experience is smooth, efficient and user-friendly. Whether you are new to investing or more experienced, Trading 212 is an excellent platform that I would happily recommend to others. A brilliant app that makes investing simple!
Pakviestas
Easy to use and fantastic features
Easy to use and fantastic features
Pakviestas
Easy to operate app for everyone!
Easy to operate app for everyone!
Pakviestas
Good platform for all my investments in…
Good platform for all my investments in one place. I have ISA and recently transferred my SIPP. I have a general investment account link to 121 debit card.
Pakviestas
Awesome service and app
Awesome service and app. Well done guys :)
Pakviestas
Everything is just so easy to use
Everything is just so easy to use. You can see at a glance how everything is doing.
Pakviestas
Just a great platform user friendly 0…
Just a great platform user friendly 0 commissions with the pie attachment whats not to like choosing 212 compared to other platforms is literally a no brainer
Pakviestas
Great app easy to move money in/out…
Great app easy to move money in and out. Good to see how much interest you are making.
Pakviestas
Easy to use and intuitive
Easy to use and great dashboard to see what’s going on. Moved my stocks and shares ISA from Barclays and not looked back.
Pakviestas
Easy to use app
Easy to use app, simple processes, good rate of return and regular updates on interest earned.
Pakviestas
Quick and easy
I found that it was quick and easy to open an account; transfer funds in and out, best of all, to sit back and watch the monies increase.
I would recommend Trading 212
Pakviestas
App is easy to use
The savings product i have has a good rate of return and I get daily updates. App is really easy to use
Pakviestas
212 has been a good discovery 6 years ago
212 has been a good discovery. Excellent platform for investment, secure and user friendly. Very good interest rate and good ISA
Pakviestas
Love it
Love it. Simple for a complete beginner to navigate. Perfect!
Pakviestas
The best app around
The best app around, so easy to use and navigate… makes investing easy.
Pakviestas
Easy access to transfer money.
Easy access to transfer money.
Daily updates regarding interest.
Pakviestas
Great platform
Great platform, easy to navigate and buy/sell. Good statements are available.
Pakviestas
Trading 212 is very transparent
Trading 212 is very transparent, open and clear with their activities. No outrageous deductions or charges. I recommend it for everyone interested in investment
Pakviestas
Good and efficient
Good and easy to use with lots of products and investment options
Pateikiami keli teigiami mūsų klientų atsiliepimai
Mūsų apdovanojimai
Dažniausiai užduodami klausimai
Kokia yra IRulya Therapeutics akcijos kaina?
Dabartinė IRulya Therapeutics kaina yra 33,08 $.
Koks yra IRulya Therapeutics52 savaičių maksimumas?
52 savaičių maksimumas IRulya Therapeutics yra 908 $.
Koks yra IRulya Therapeutics 52 savaičių žemiausias lygis?
52 savaičių žemiausias IRulya Therapeutics kursas yra 15,1 $.
Koks yra IRulya Therapeutics savaitės rezultatas?
Per pastarąją savaitę IRulya Therapeutics kaina pasikeitė 3,28 %.
Koks yra IRulya Therapeutics mėnesio našumas?
Per pastarąjį mėnesį IRulya Therapeutics kaina pasikeitė 5,52 %.
Koks yra IRulya Therapeutics 3 mėnesių rezultatas?
Per pastaruosius tris mėnesius IRulya Therapeutics kaina pasikeitė 78,43 %.
Koks yra IRulya Therapeutics 6 mėnesių rezultatas?
Per pastaruosius šešis mėnesius IRulya Therapeutics kaina pasikeitė 20,73 %.
Koks yra IRulya Therapeuticsmetinis našumas?
Per pastaruosius metus IRulya Therapeutics kaina pasikeitė −90,91 %.